Symptoms of Hormone Imbalance in Women

Symptoms of hormone imbalance in women may begin as early as the late twenties to the forties. Symptoms of hormone imbalance in women tend to increase as a woman ages, especially if ignored in the earlier years. Hormone imbalance symptoms can be any one or more of the following (1,2):

• Allergy symptoms


• Depression, fatigue, and anxiety


• Endometriosis


• Fibrocystic breasts


• Hair loss and facial hair growth


• Headaches, dizziness, and foggy thinking


• Low sex drive


• Osteoporosis


• PMS


• Urinary tract infections and incontinence


• Uterine fibroids


• Weight gain, water retention and bloating


• Wrinkly skin

Symptoms of hormone imbalance are caused primarily by the incorrect relationship between progesterone and estrogen levels in the body. The two female hormones, estrogen and progesterone, exist in a delicate balance. Variations in that balance can have a dramatic effect on your health, resulting in symptoms of hormone imbalance. The amounts of these hormones that the woman’s body produces from month to month can vary, depending on factors such as stress, nutrition, exercise and most importantly – ovulation or the lack of ovulation (3).

In the first 10-12 days of the menstrual cycle, only estrogen is produced in the female body. If ovulation occurs, then progesterone is produced by the ovaries. On day 28 or so, levels of both hormones drop, resulting in menstruation. However, if ovulation did not occur, you can still have the menstrual period, but the estrogen is never “balanced” by progesterone, which needed ovulation to trigger its production. And this results in symptoms of hormone imbalance appearing – you have estrogen but progesterone production drops to very low levels.

In the industrialized countries, women take birth control pills, are exposed to household chemicals at home, car exhaust and other environmental xenoestrogens. In addition, women often have stressful lives, eat processed foods or skip meals, take synthetic estrogen HRT (hormone replacement therapy) and have hysterectomies. All these factors can add more estrogen to the female body, resulting in excess estrogen which will cause hormone imbalance symptoms.
1. The Truth About Low Thyroid: Stories of Hope and Healing for Those Suffering with Hashimoto’s Low Thyroid Disease – August 30, 2016 Dr. Joshua J. Redd
2. Why Do I Still Have Thyroid Symptoms? when My Lab Tests Are Normal: a Revolutionary Breakthrough in Understanding Hashimoto’s Disease and Hypothyroidism, 1st Edition, Dr. Datis Kharrazian
3. http://www.health.com/health/gallery/0,,20723100,00.html

Symptoms of Hormone Imbalance in Women

When it comes to menopausal hormone therapy, women are left guessing at the risks | Margaret McCartney

As a freshly minted doctor in the early 1990s, I attended lectures describing hormone replacement therapy – which is now known, in this context, as MHT, menopausal hormone therapy – as close to a miracle cure-all. Women shouldn’t worry their pretty little heads, it was implied at the time, because doctors knew best – and this treatment would not only make them feel fantastically sexy, but prevent cardiovascular disease and strokes. Promotion, back then, went beyond recommending it for menopausal symptoms. It was the elixir of life, preventing future illness and making women look younger.

Let’s sidestep the sexist and ageist undertones of that era, and fast forward to the publication of the Women’s Health Initiative study in 2002, which found that the treatment increased the risk of breast cancer. For every 10,000 person-years of combination menopausal hormone therapy use (oestrogen plus progesterone), there were seven more heart attacks, eight more strokes, eight more blood clots on the lungs, and eight more invasive breast cancers. In the ensuing years, the amount of menopausal hormone replacement being prescribed fell by half.

In November 2015, the National Institute for Health and Care Excellence (Nice) published new guidance on treating the menopause. In a press release, it suggested that menopausal hormonal treatment was being underprescribed, and GPs needed to prescribe it more. “For the last decade, some GPs have been worried about prescribing HRT, and women worried about taking it …” it wrote. “For health professionals, the guideline should boost their confidence in prescribing HRT, having fully discussed the woman’s individual circumstances with her.”

That seemed pretty clear, but now a new UK study apparently shows that the risks of breast cancer have been underestimated and “nearly tripled” when women were taking hormone treatment for menopause.

So should I still feel confident about prescribing it? Is this a high or a low risk? Is it a risk worth taking? Well, that depends on the patient. There will be women who regard the risks as reasonable because they experience such enormous benefits. Then there are other women who would consider a much smaller risk of serious harm unacceptable. Autonomy rules, and there is no “correct” answer (although I suspect the General Medical Council would be quick to hold doctors to account for what was viewed as reckless prescribing). But to make that autonomy meaningful, we have to be able to make a rational, informed choice. That needs quality data. So what does the latest study tell us?

It’s a prospective, cohort study, which specifically looked for hormone use and age at menopause, which many other studies have not. Just over 39,000 women had their age at menopause documented, and 775 of these developed breast cancer. They found that the women who used combination MHT were more likely to develop breast cancer by a factor of 2.7; this risk dissipated when the women stopped the MHT, but rose the longer it continued.

The NHS offers detailed decision aids for treatments for everything from arthritis to angina – but none on the menopause

We need to put this into context: 2.7 times a small number is still a small number, so you need to know what your risk was to start with. For a woman aged between 50-70, the risk of breast cancer is about 5%. Is an increase to about 13% for the years a woman is taking the hormones worth it? I don’t know. But I am also concerned as to whether this cohort are truly representative of the population at large, because the women who volunteered for this study were not asked to participate randomly, but were recruited through newsletters sent out by a breast cancer charity. They may, therefore, have been more likely to have a family member with breast cancer, or share the same environmental risks as friends with breast cancer, and so faced a higher risk to start with.

I also don’t reliably know how much the change in breast cancer risk is per woman: as one of the authors, Dr Michael Jones, told me: “Our results are internally consistent and we can talk about relative changes, but we cannot make external extrapolations in absolute risk to the whole UK.” In other words, care is needed – and we will need this data to be replicated in other data sets before we can be confident that it applies equally to other women.

Uncertainty is a hallmark of medical decision making. If a woman develops breast cancer while taking MHT, no one can be sure whether it would have happened in any case. We need context. We can’t control our genes, but what other risk factors can we at least partially control? Cancer Research UK says that 9% of breast cancers are linked to obesity, 6% to excess alcohol, and 3% to insufficient physical activity. In context, MHT is linked to 3% of all breast cancers. If this has been underestimated, as the new study claims, by up to 60%, that means that up to 5% of all breast cancers could be linked to MHT. But there are so many ongoing uncertainties that I think pinning it down to the last percentage point makes this look more accurate than it is.

So what do we do in the meantime? GPs are under enormous pressure anyway – each of our appointments is just 10-12 minutes long, with an average of 2.5 problems being discussed, so there’s barely time to make a safe diagnosis, never mind discuss most of the side effects for each possible treatment. There has been a quiet revolution in medicine in the last decade, a realisation that making choices is often hard to do well. There are now a wealth of “shared decision aids” online, based on high-quality evidence and with the emphasis on assisting patients, not dictating “choice”. They work in different ways; some are online or DVD-based, and they usually try and lay out the pros and cons of treatments in a logical way, giving the person enough time and information to make high-quality decsions.

These have been shown to help people make better decisions about treatment choices – and using them before or after GP appointments is a useful way of making oneself surer of healthcare choices.

The NHS has a website devoted to detailed decision aids for treatments for everything from arthritis to angina – but none, so far, on the menopause. Nice does have an information section on its website about the pros and cons of hormone treatment for menopause, but doesn’t provide any numbers about the risks – or define what they mean by “low-risk”, in common with other US decision aids – and while that might be enough information for some women, it’s unlikely to be detailed enough for others.

We need better quality information that doesn’t offer more certainty than we actually have: we are in a new era of medicine, and honesty about the knowns and unknowns, and the limitations of our knowledge is essential. I will continue to prescribe MHT, but when it comes to discussing risks and benefits, I suspect I will be answering many questions with an honest “I don’t know”.

When it comes to menopausal hormone therapy, women are left guessing at the risks | Margaret McCartney

Hormone Therapy At Menopause Fails To Halt Heart Illness Progression

More than a decade ago the Women’s Overall health Research made surprising and essential outcomes when it showed that broad use of hormone substitute treatment did not minimize cardiovascular threat in publish-menopausal females. But the study also led to speculation  that hormone therapy  might be beneficial when delivered closer to the time of menopause. Now a review published in Annals of Internal Medicine demonstrates that menopausal hormone therapy (MHT) might have some favorable results on some cardiovascular danger elements but it does not lessen the progression of atherosclerosis.

In the review, called KEEPS (Kronos Early Estrogen Prevention Research), 727 menopausal women were randomized to placebo or one particular of two types of low dose hormone treatment (oral conjugated equine estrogens or transdermal 17β- estradiol). Following four years there was no distinction between the groups in the primary endpoint of the research, which was the progression of atherosclerosis as measured by carotid artery intima–media thickness (CIMT). There was also no big difference in the coronary artery calcium scores. Ladies in the equine estrogen group had enhancements in their lipid profiles (decrease in LDL and increase in HDL) while women in the transdermal group had improved insulin sensitivity. There was no big difference in the incidence of significant adverse occasions.

The investigators supplied several explanations for the findings, like a research population at reduced danger for athersosclerosis, a reasonably quick examine duration, and the use of minimal dose but not large dose estrogen. “To the extent that these imaging strategies predict CVD events, our findings recommend that MHT neither is a chance nor is protective in the population studied,” they wrote. The study was not powered to appear at clinical events.

Andrew Kaunitz, a expert in women’s wellness and menopause at the University of Florida, explained that although it even now remains unclear what the prolonged term effects of hormone treatment will be on cardiovascular occasions, the study “does not assistance using hormone treatment to avert CVD events.”

Hormone Therapy At Menopause Fails To Halt Heart Illness Progression

Boys who produce autism "exposed to higher ranges of hormone in the womb"

The lead to of the elevated hormone amounts is unclear, it is considered to be a genetic problem.

The researchers stated due to the fact the hormones have been discovered in the amniotic fluid, which surrounds the child in the womb, the supply is a lot more most likely to be the infant than the mother. They strategy additional exams on the mother’s hormones to create this.

Autism is a broad spectrum of disorders affecting social interaction, and occasionally speech and understanding.

It is believed up to one in one hundred children might be impacted by autism spectrum disorders.

The findings had been published in the journal Molecular Psychiatry.

Lead writer Simon Baron-Cohen, professor of developmental psychopathology at Cambridge, stated: “We previously knew that elevated prenatal testosterone is connected with slower social and language improvement, much better focus to detail and a lot more autistic traits.

“Now, for the initial time, we have also proven that these hormones are elevated in youngsters clinically diagnosed with autism.”

The study drew on 19,500 amniotic-fluid samples stored in a Danish biobank from folks born in between 1993 and 1999.

The researchers identified samples from mothers who gave birth to 128 boys later on diagnosed with an autism-spectrum condition.

Simply because some of the hormones are made in considerably higher quantities in males than in females, the obtaining may possibly help clarify why autism has an effect on far more boys, the researchers said.

Prof Baron-Cohen stated: “These new outcomes are especially striking because they are located across all the subgroups on the autism spectrum, for the very first time uniting people with Asperger Syndrome, traditional autism, or Pervasive Developmental Disorder Not-Otherwise-Specified.

“We now want to check if the very same locating is found in females with autism.”

However there were some boys who did not have autism who had been exposed to higher amounts of hormones in the womb and some boys with autism who have been exposed to reduced levels of hormones, so the outcomes cannot be utilised to create a prenatal check for autism, specialists mentioned.

Dr Rosa Hoekstra, Lecturer in Psychology, The Open University, explained: “This paper is the first to recommend that male foetuses who later on produce autism may have been exposed to somewhat larger ranges of prenatal steroid hormones, as measured in amniotic fluid, compared to male foetuses who create typically following birth.

“Moreover, this study centered on comparisons between boys with autism and boys with no psychiatric diagnoses or studying difficulties. As the authors stage out themselves, it is as nevertheless unknown if similar distinctions apply to ladies with autism, and to kids with other problems, this kind of as ADHD or intellectual disability.”

Prof Richard Sharpe, of the Healthcare Analysis Centre for Reproductive Well being at the University of Edinburgh, mentioned: “Finding the fetal leads to of autism-spectrum ailments is a challenging activity, so this carefully made research wants to be viewed in this context.

“It is an important initial phase.

“At face value this seems to fit with the previously argued hypothesis that ‘overexposure’ to fetal androgens could increase the chance of autistic disorders, and would also fit with the increased prevalence of these disorders in boys, who are naturally exposed to increased amounts of fetal androgens than are girls.

“However, as the authors are mindful to point out, if you examine real hormone levels (I.e. Testosterone) in the amniotic fluid samples in their research, there is no clear distinction among hormone ranges in controls and in people who went on to build an autistic disorder.

“There could be several explanations for this, this kind of as variation in personal sensitivity to hormones or that the time widow investigated is also early to detect a correct elevation of hormone amounts as the amniocentesis procedure from which these samples are collected is usually undertaken in between 15-twenty weeks.”

He advised there may be option explanations including that kids with autism are more sensitive to hormone amounts or their bodies use them in a distinct way to normal.

He explained: “We now know that subtle variations in fetal growth are an essential determinant of later disease, which may be lifelong.

“Studying this in humans is exceptionally tough because of the obvious limitations in accessing what is occurring in the foetus within the womb, so investigations this kind of as the current research have to be viewed as pioneering.”

A paper published in March in the New England Journal of Medication found that individuals diagnosed with autism missed essential genetic markers for brain cells that are supposed to create prior to birth.

A Norwegian study published last year discovered that taking folic acid dietary supplements in early pregnancy was linked to a reduce danger of autistic disorder. Folic acid is required to fuse the spinal cord in early fetal advancement.

Vaccination has been feared as a prospective cause of autism right after a review by Andrew Wakefield, published in the Lancet healthcare journal in 1998, linked the measles-mumps-rubella vaccine to an enhanced threat of building the situation.

The Lancet retracted the examine in 2010, citing “false” claims, and the British Health care Journal referred to as it a fraud in a report the following year.

Boys who produce autism "exposed to higher ranges of hormone in the womb"